Bradley J. Monk, MD, on Platinum-Resistant Recurrent Ovarian Cancer: Pembrolizumab Plus Weekly Paclitaxel

Posted: Friday, April 17, 2026

Bradley J. Monk, MD, of Florida Cancer Specialists, reviews the results of the final analysis of the phase III ENGOT-ov65/KEYNOTE-B96 trial, which investigated whether adding pembrolizumab to weekly paclitaxel, with or without bevacizumab, improves progression-free survival and overall survival compared with weekly paclitaxel, with or without bevacizumab, in participants with platinum-resistant recurrent ovarian cancer who had received one to two previous systemic regimens.